Marked and reversible circulating insulin-like growth factor-1 elevation during teprotumumab N01 treatment for thyroid eye disease with limited correspondence to glycemic changes - Scorecard - MDSpire

Marked and reversible circulating insulin-like growth factor-1 elevation during teprotumumab N01 treatment for thyroid eye disease with limited correspondence to glycemic changes

  • By

  • Wei Zhao

  • Lingli Zhou

  • Ying Gao

  • Xianghai Zhou

  • Xueyao Han

  • Xiuying Zhang

  • Linong Ji

  • July 15, 2026

Share

Clinical Scorecard: Significant and Reversible Increases in Circulating Insulin-like Growth Factor-1 During Teprotumumab N01 Therapy for Thyroid Eye Disease with Limited Association to Glycemic Variations

At a Glance

CategoryDetail
ConditionThyroid Eye Disease (TED)
Key MechanismsInsulin-like growth factor-1 receptor (IGF-1R) inhibition
Target PopulationPatients with moderate-to-severe TED
Care SettingRetrospective cohort study

Key Highlights

  • Teprotumumab N01 treatment resulted in a median peak IGF-1 concentration of 649.5 ng/mL.
  • IGF-1 increased significantly after treatment initiation, with a 4.2-fold increase from baseline.
  • Glycemic markers showed modest increases during treatment.
  • IGF-1 dynamics were not independent correlates of glycemic changes.
  • IGF-1 levels returned to baseline by 6–9 months post-treatment.

Guideline-Based Recommendations

Diagnosis

  • Diagnosis of moderate-to-severe TED based on clinical evaluation.

Management

  • Teprotumumab N01 is recommended for treatment of moderate-to-severe TED.

Monitoring & Follow-up

  • Monitor serum IGF-1 and glycemic markers during and after treatment.

Risks

  • Monitor for potential glycemic deterioration, especially in patients with baseline dysglycemia.

Patient & Prescribing Data

92 patients with moderate-to-severe TED

Teprotumumab N01 administered as 10 mg/kg initial dose followed by 20 mg/kg for subsequent infusions.

Clinical Best Practices

  • Conduct regular assessments of IGF-1 and glycemic markers during treatment.
  • Consider baseline glycemic status when evaluating treatment effects.

Related Resources & Content

Original Source(s)

Marked and reversible circulating insulin-like growth factor-1 elevation during teprotumumab N01 treatment for thyroid eye disease with limited correspondence to glycemic changes

  • by Wei Zhao, Lingli Zhou, Ying Gao, Xianghai Zhou, Xueyao Han, Xiuying Zhang, Linong Ji

  • July 15, 2026

Related Content

Comparative study of the therapeutic effects of different medications on DM-associated dry eye syndrome after vitrectomy

Are GLP-1s Linked to Optic Neuropathy?

A nationwide Swedish cohort found a higher relative risk of anterior ischemic optic neuropathy among GLP-1 receptor agonist users, but the overall risks were low.

AI Screening for Diabetic Retinopathy